01:30 , Jul 13, 2019 |  BioCentury  |  Tools & Techniques

Broadening role for external control arms in clinical trials

External control arms are moving from theory to practice as drug developers begin to use them to make internal go/no-go decisions for clinical programs and to support regulatory applications. The field is largely split between...
15:53 , Jul 3, 2019 |  BioCentury  |  Emerging Company Profile

Kymera: a systematic approach to protein degradation

With a computational drug discovery platform and a proprietary library of E3 ligases and binders, Kymera believes it can accelerate the discovery and development of protein degraders. Protein degradation is entering the mainstream as a...
23:26 , Jun 28, 2019 |  BC Extra  |  Preclinical News

OncoSec jumps into TNBC CAR T therapy via Dana-Farber deal

By partnering with a Dana-Farber antibody engineering expert and leveraging the institute’s cell manufacturing capabilities, cytokine therapeutics company OncoSec is expanding into CAR T cell therapies for solid tumors. The deal highlights how manufacturing-savvy academic...
00:51 , May 31, 2019 |  BC Innovations  |  Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

A growing crop of researchers and companies are tackling cancer drug resistance by preempting tumors’ tendencies to adapt, rather than responding to resistance after it develops. Though still in their infancy, these therapies could get...
15:32 , May 21, 2019 |  BC Extra  |  Company News

Merck bets on HIF2As with Peloton takeout ahead of planned listing

Days before Peloton was to price an IPO that would fund Phase III testing of its HIF2A program to treat kidney cancer, the biotech has elected instead to take a buyout offer from Merck &...
14:20 , May 14, 2019 |  BC Innovations  |  Distillery Therapeutics

GSK3A inhibition restores asparaginase sensitivity in resistant ALL, AML

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL); acute myelogenous leukemia (AML) Cell culture and mouse studies suggest inhibiting GSK3A could help treat asparaginase-resistant T cell and B cell ALL and AML. In a T...
01:50 , May 10, 2019 |  BC Innovations  |  Targets & Mechanisms

The tumor microbiome emerges as a new source of translational opportunities

While the gut microbiome has attracted wide attention for its influence on anti-tumor immunity, a growing body of research suggests microbes living in the tumor itself may play even broader roles in cancer. At least...
12:35 , May 8, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
19:57 , Apr 16, 2019 |  BC Innovations  |  Distillery Therapeutics

WRN inhibition for four cancer types with microsatellite instability

DISEASE CATEGORY: Cancer INDICATION: Colorectal cancer; endometrial cancer; gastric cancer; ovarian cancer Cell culture and mouse studies suggest inhibiting WRN could help treat colorectal, ovarian, endometrial and gastric cancers with microsatellite instability. In over 500...